INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

To Commissioner For Patents; Enclosed herewith is a Form PTO-1449, any required copies of documents listed thereon, and any concise explanation of their relevance is indicated below per 37 CFR 1.97.

| Application Number | |
|------------------------|------------------|
| Filing Date | CONCURRENTLY |
| First Named Inventor | FABIEN GUILLORIT |
| Group Art Unit | LA178 1/1/2 34 |
| Examiner Name | Maria El 25051 |
| Attorney Docket Number | US030342 |

- 図 Please charge any required fee under §1.17(i) or §1.17(p) or any other required fee (except the issue fee) to Account No. 14-1270.
- I certify that these documents were first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three (3) months ago.
- I certify that none of these documents were cited in any communication from a foreign Patent Office
 in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable
 inquiry, none of these documents was known to any individual designated in §1.56(c) more than three
 (3) months ado.
 - Applicant hereby petitions under §1.97(d) that this IDS be considered after final Action or Notice of Allowance, pays the fee under §1.17(p) as indicated below, and I certify 1. or 2. as indicated above.
 - A fee under §1.17(p) is not required under §1.97(c), after the first Action on the merits and more than (3) months after the date of application or RCE, because I certify 1. or 2. as indicated above.
 - A copy of the citations is not required because they were previously submitted or cited in the parent application (or in U.S. patent application Ser. No. Plate relied on for an earlier effective filing date under 35 U.S.C. 120).
 - [] A copy of the U.S. patent(s) and patent application publication(s) in all U.S. national patent applications filed after June 30, 2003, and in all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003 under 37 CFR 1.491(b), are not required.
 - A concise explanation of the relevance of each non-English document, as understood by the individual designated in §1.56(c) most knowledgeable about the contents, is enclosed per §1.98(a)(3).

The concise explanation of the relevance of any non-English document, as understood by the individual designated in §1.56(c) most knowledgeable about the contents, is that the document is/was:

- |X| cited in the specification or considered in drafting the specification of this application;
- previously submitted or cited in the parent application (or in a related patent application Ser. No.______);

[] cited as an "X", "Y", or "A" document in a foreign Patent Office search report in a foreign counterpart application, a copy of which report is also enclosed.

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED | | | | | |
|---|---------------|-----------------------------------|--------|--|--|
| Name (Print Type) | Yan Glickberg | Registration No. (Attorney/Agent) | 51,742 | | |
| Signature | Man Glichberg | Date 3- 20-0 | 06 | | |

IAPZORSE'GTOTIVIO BE NAR 2006 / OSBIOBA (OB-OS)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

| Complete if Known | | | |
|------------------------|------------------|--|--|
| Application Number | AM 85,72836 | | |
| Filing Date | CONCURRENTLY | | |
| First Named Inventor | Fabien GUILLORIT | | |
| Art Unit | 4178 | | |
| Examiner Name | Maria El zoobi | | |
| Attorney Docket Number | US030342 | | |

| | | | | DOCUMENTS | |
|-----------------------|--------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No.1 | Document Number Number-Kind Code ^{2 of known)} | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| /M.E./ | - | us- 6059092 | 05-09-2000 | HICKMAN | |
| M.E./ | | ^{US-} 6152856 | 11-28-2000 | STUDOR et al. | |
| /M.E./ | | US- 20010056226A1 | 12-27-2001 | ZODNIK et al. | |
| | | US- | | | |
| | - | US- | | | |
| | | 96 | | | |
| | | US- | | | |
| | 1- | US- | | | |

| | | | PATENT DOCL | | | |
|-----------------------|--------------|---|---------------------|--|---|---------|
| Examiner Initials* | Cite No.1 | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages | ١. |
| | | Country Code ³ "Number ⁴ "Kind Code ⁵ (if known) | MM-DD-YYYY | | Or Relevant Figures Appear | T°. |
| /M.E./ | | WO02062425A1 | 08-15-2002 | WATTERSON et al | | |
| /M.E./ | | WO0182789A | 11-08-2001 | MAULT et al. | | |
| /M.E./ | | WO0112269 | 02-22-2001 | PYLES et al. | | |
| /M.E./ | | WO0187426 | 11-22-2001 | MYNHARDT | | |
| - | | | | | | \perp |
| | | | | | | _ |

Examiner Signature | //Maria El-zoobi/ Date Considered | 01/18/2008 |
EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 699. Draw line through citation if not in conformance and not separate the conformance in the conformance and not separate the conformance in the conform

*EAJAMPEL: milag if reference considered, whether or not citation is in conformance with MPELP 080, Draw line through clation if not in conformance and not considered, include copy of this form with next communication to applicant. *Applicants' using cellation designation number (poly). *See Kinds Codes of USPTO Patient Documents at https://www.uspto.org/ or MPEP 90.104. *Enter Office that issued the document, by the two-letter code (WIPO) Standard ST.3.) *For Japanese patient Cocuments, the indication of the year of the reigh of the Emperor must proceed the sental number of the patient focument. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR, 197 and 1.98. The intermetation is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentishly is operanted by 39 U.S.C. 122 and 37 CFR, 114. This collection is estimated to Fourist b complete to the public which is the complete displaced in the complete displaced in the complete displaced in the complete displaced in the USPTO. Time well vary depending upon the individual case. Any comments of time your requires to complete this form and/or suppersions for reducing this burden, should be sent to the Chief Information. Officer, U.S. Patient and Trademark Office, P.D. Sox 1450, Alexandria, V.A. 2231-31450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.